ZBH Stock Forecast & Price Target

Zimmer Biomet Holdings is the leading player in the orthopedic reconstructive market with a strong presence in the United States, Europe, and Japan. The company has a diverse product portfolio, including large joints, extremities, trauma, sports medicine, and spinal devices, which positions it well in the growing orthopedic market. Despite the crosscurrents dampening the 1Q26 report and management changes, Zimmer Biomet's solid sales, margins, and EPS performance, along with its unchanged capital allocation strategy and strategic transformation goals, show strong potential for growth. However, potential risks such as competition, slowdown in core end markets, and tariff impact may limit the company's ability to gain market share and lead to EPS growth constraints, making it a Hold-rated investment with a 2.0% revenue and $9.71 EPS growth rate for 2028.

Zimmer Biomet Holdings is the largest publicly traded musculoskeletal company and has a long history as a standalone MedTech firm, with a strong focus on orthopedic reconstructive implants. While the recent acquisition of Biomet has expanded the company's presence and market share, the majority of Zimmer's revenue still comes from sales of large joints, which can be subject to fluctuations in demand. Additionally, the company's recent restructuring efforts and go-direct transition pose near-term execution challenges that may impact its ability to meet its long-term financial targets, leading to a negative outlook.